On June 16, 2023 Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke reported Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting (Press release, Prescient Therapeutics, JUN 16, 2023, https://www.proactiveinvestors.com.au/companies/news/1018069/prescient-therapeutics-showcases-cell-therapy-data-at-prestigious-isct-conference-1018069.html?utm_source=rss&utm_medium=rss&utm_campaign=prescient-therapeutics-showcases-cell-therapy-data-at-prestigious-isct-conference [SID1234632750]). The team briefed an expert cell therapy audience on two abstracts in a move Yatomi-Clarke believes exemplifies the Prescient pipeline’s utility and innovation. The CEO says there’s plenty of news to come in FY24 as Prescient readies CellPryme and OmniCAR for clinical studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!